SCHEMBL3383072

SCHEMBL3383072

Cc1ccc(C(Cl)C(=O)O)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.46
SMN1; SMN2 Q16637 5/20 0.46
ALDH1A1 P00352 5/20 0.46
POLB P06746 1/20 0.45
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
TP53 P04637 1/20 0.42
AKR1C3 P42330 1/20 0.41
AKR1C2 P52895 1/20 0.41
ACHE P22303 1/20 0.41
ALOX5 P09917 1/20 0.41
CES2 O00748 2/20 0.41
CES1 P23141 2/20 0.41
SRD5A2 P31213 1/20 0.40
HPGD P15428 1/20 0.40
CNR1 P21554 1/20 0.40
CNR2 P34972 1/20 0.40
KEAP1 Q14145 1/20 0.39
NFE2L2 Q16236 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11836955 0.94 FFAR1 (0.46) LMNASMN1; SMN2ALDH1A1POLBMEN1
SCHEMBL1398802 0.83 LMNA (0.44) LMNASMN1; SMN2ALDH1A1POLBMEN1
SCHEMBL3993198 0.82 SMN1; SMN2 (0.42) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL8657004 0.82 SMN1; SMN2 (0.42) LMNASMN1; SMN2ALDH1A1POLBMEN1
SCHEMBL7282243 0.80 ALOX5 (0.48) LMNASMN1; SMN2ALDH1A1MEN1KMT2A
SCHEMBL2454097 0.79 CYP2C9 (0.47) LMNAPOLBMEN1KMT2ACES2
SCHEMBL3739027 0.79 SRC (0.50) LMNAALDH1A1MEN1KMT2ACES2
SCHEMBL11749506 0.78 SMN1; SMN2 (0.48) LMNASMN1; SMN2ALDH1A1POLBMEN1
SCHEMBL29009949 0.78 PTGS2 (0.39) LMNAMEN1KMT2AAKR1C3AKR1C2
SCHEMBL5325296 0.78 SRC (0.56) LMNASMN1; SMN2ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2427435-B1 SUBSTITUTED PHENYLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS MEDIFRON DBT INC (KR) 2017-06-14 EP disclosed
US-9624209-B2 Substituted phenylureas and phenylamides as vanilloid receptor ligands GRUENENTHAL GMBH (DE) 2017-04-18 US disclosed
US-9624209-B2 Substituted phenylureas and phenylamides as vanilloid receptor ligands GRUENENTHAL GMBH (DE) 2017-04-18 US disclosed
WO-2016147132-A1 A PROCESS FOR THE PREPARATION OF DROXIDOPA Piramal Enterprises Limited (IN) 2016-09-22 WO disclosed
US-9120756-B2 Substituted phenylureas and phenylamides as vanilloid receptor ligands GRUENENTHAL GMBH (DE) 2015-09-01 US disclosed
US-9120756-B2 Substituted phenylureas and phenylamides as vanilloid receptor ligands GRUENENTHAL GMBH (DE) 2015-09-01 US disclosed
US-20150099728-A1 Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands MEDIFRON DBT INC. (KR) 2015-04-09 US disclosed
US-20150099728-A1 Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands MEDIFRON DBT INC. (KR) 2015-04-09 US disclosed
US-8946204-B2 Substituted phenylureas and phenylamides as vanilloid receptor ligands GRUENENTHAL GMBH (DE) 2015-02-03 US disclosed
US-8946204-B2 Substituted phenylureas and phenylamides as vanilloid receptor ligands GRUENENTHAL GMBH (DE) 2015-02-03 US disclosed
US-20120258946-A1 Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands GRUENENTHAL GMBH (DE) 2012-10-11 US disclosed
US-20100331381-A1 Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands GRUENENTHAL GMBH (DE) 2010-12-30 US disclosed
US-20100331381-A1 Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands GRUENENTHAL GMBH (DE) 2010-12-30 US disclosed
EP-1072580-B1 PROCESS FOR PRODUCING CHLOROMETHYLPHENYLACETIC ACID IHARA CHEMICAL IND CO (JP) 2010-12-01 EP disclosed
WO-2010127856-A1 SUBSTITUTED PHENYLLUREAS AND PHENYLAMIDES AS VANILLOID RECEPTOR LIGANDS Grünenthal GmbH (DE) 2010-11-11 WO disclosed
EP-1562900-A4 POLYMORPHS OF BICIFADINE HYDROCHLORIDE DOV PHARMACEUTICAL INC (US) 2006-07-12 EP disclosed
EP-1562900-A1 POLYMORPHS OF BICIFADINE HYDROCHLORIDE DOV Pharmaceutical Inc. (US) 2005-08-17 EP disclosed
WO-2004043920-A1 POLYMORPHS OF BICIFADINE HYDROCHLORIDE DOV PHARMACEUTICALS, INC. (US) 2004-05-27 WO disclosed
US-6414186-B1 REACTING METHYLPHENYLACETIC ACID WITH CHLORINE GAS, IN INERT SOLVENT, UNDER IRRADIATION WITH LIGHT OR IN PRESENCE OF RADICAL INITIATOR IHARA CHEMICAL INDUSTRY CO., LTD. (JP) 2002-07-02 US disclosed
EP-1072580-A1 PROCESS FOR PRODUCING CHLOROMETHYLPHENYLACETIC ACID Ihara Nikkei Chemical Industry Co., Ltd. (JP) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331381-A1 Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands TRPV1, TRPV5, TRPV2 LMNA 3698/4885SMN1; SMN2 3477/4885ALDH1A1 2236/4885
US-20150099728-A1 Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands TRPV1, TRPV5, TRPV6 LMNA 3395/4885SMN1; SMN2 3176/4885ALDH1A1 2943/4885
US-20120258946-A1 Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands TRPV1, TRPV5, TRPV6 LMNA 3395/4885SMN1; SMN2 3176/4885ALDH1A1 2943/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.